TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00004092

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or subcutaneously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Description: Given IV or subcutaneously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: carboplatin
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: thiotepa
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: peripheral blood stem cell transplantation
Description: Patients receive autologous peripheral blood stem cells

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: peripheral blood stem cell transplantation
Description: Patients receive autologous peripheral blood stem cells
Study: NCT03500640

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: DPP Intensive: 30-minute calls
Description: Ongoing DPP intervention and behavioral progress review to prevent relapse and improve cardiometabolic and functional health targets as keys to healthy aging.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: DPP Support: 15-minute calls
Description: No further behavioral intervention materials provided; phone-contacts for mutual social support and accountability
Study: NCT04676295

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Face-to-face and web-based lifestyle intervention
Description: Families are provided at baseline with one 60 min face-to-face dietary counseling session with nutritionist using family-oriented motivational interviewing and solution focusing techniques. The intervention continues in an interactive web-based portal where different modules include assignments, activities, and tests and related videos targeting five cardiovascular health-linked behaviors: 1) improving quality of fat in the diet, 2) increasing the consumption of foods rich in fiber, 3) decreasing the use of salt, 4) increasing physical activity and 5) reducing smoking.
Study: NCT01961271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buprenorphine transdermal patch
Description: Please see Arm Description.
Study: NCT01951560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: By infusion over 1 hour

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Isotonic saline solution
Description: By infusion over 1 hour
Study: NCT00056979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAMPATH-1H

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anti-CD45

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FK506

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Study: NCT02186574

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tenofovir disoproxil

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Study: NCT03084692

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Therapeutic Yoga and Resistance Exercise
Description: Combined Program of Yoga and Resistance Exercise
Study: NCT03259087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
Study: NCT02316704

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 OsseoTi coted acetabular component

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: THA with G7 OsseoTi coted acetabular component
Study: NCT03433482

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY liquid
Description: At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MenACWY liquid
Description: At visit 1 (day 1), each subject will receive a single dose of the investigational MenACWY liquid vaccine (GSK3536820A) aged for approximately 24 months in Phase 1 of the study (subjects randomized to study arm ACWY_Liq24) or vaccine aged for 30 months in Phase 2 of the study (subjects randomized to study arm ACWY_Liq30), administered by intramuscular injection in the deltoid of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MenACWY
Description: At visit 1 (day 1), each subject will receive a single dose of the MenACWY vaccine in the Phase1 of the study (subjects randomized to study arm ACWY_1) or in phase 2 of the study (subjects randomized to study arm ACWY_2), administered by intramuscular injection in the deltoid of the non-dominant arm.
Study: NCT03259087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3866
Description: Single IV infusion of 200 mg administered over 30 minutes (±5 minutes) on Day 1 of each treatment period.
Study: NCT02518971

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin
Description: 0.4 mg daily
Study: NCT01313429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogenic tumor Cell Vaccine (K562)
Description: 4 vaccines consisting of approximately 2.5E7 cells each will be delivered IM every 4 weeks for 6 months. If immune response is detected after first 6 vaccinations, 2 more may be given at 3 month intervals.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Celecoxib
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
Study: NCT02448875

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CyPass Micro-Stent
Description: Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CyPass Micro-Stent
Description: Small tube with a through-lumen designed to redirect aqueous fluid from the front to the back of the eye in order to reduce intraocular pressure. Designed to be permanently implanted in the eye.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscoelastic
Description: Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Viscoelastic
Description: Healon 5 ophthalmic viscoelastic used to increase the size of the aqueous drainage area created by the CyPass Micro-Stent
Study: NCT04100902

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ODACTRA 12 SQ-HDM Sublingual Tablet
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo sublingual tablet
Description: Subjects are randomized to either HDM-AIT or Placebo for 24 weeks of therapy
Study: NCT04145531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IM JZP-458
Description: IM JZP-458 will be administered in Part A, Cohorts 1 \& 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV JZP-458
Description: IV JZP-458 will be administered in Part B
Study: NCT04128059

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac-Combi
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac-Combi
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac-Combi
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BVRS-GamVac-Combi
Description: BVRS-GamVac-Combi, a combined vector vaccine for the prevention of Middle East respiratory syndrome, lyophilisate for the preparation of a solution for intramuscular administration

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study: NCT03487159

Intervention type: DEVICE
Group type: OTHER
Intervention: MRE (Magnetic Resonance Elastography)
Description: The device is using to evaluate liver fibrosis stage

Intervention type: DEVICE
Group type: OTHER
Intervention: MRE (Magnetic Resonance Elastography)
Description: The device is using to evaluate liver fibrosis stage
Study: NCT00314847

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Extra-Corporeal Life Support -Impella 2.5
Description: Percutaneous implantation of Impella pump for a duration of 3 days as a minimum and up to 7 days (recommended)
Study: NCT02518971

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: one capsule daily
Study: NCT02434770

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 1
Description: Each dose of bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 cell culture infectious dose 50% (CCID50)/dose and 10\^5.8 CCID50/dose, respectively.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BBIBP Bivalent Oral Poliomyelitis Vaccine Lot 2
Description: Each dose of bOPV (2 drops, 0.1 ml) contains types 1 and 3 attenuated polioviruses (Sabin), with at least 10\^6 CCID50/dose and 10\^5.8 CCID50/dose, respectively.
Study: NCT02027831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Study: NCT02183168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam suppository
Study: NCT01231919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Akt inhibitor MK2206
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: diagnostic laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study: NCT03356275

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness for Resilience in Illness: Support for Parents
Description: Mobile application focusing on emotional coping skills for parents of children and adolescents with chronic pain. Components of the module include: library of mindfulness meditations/relaxations; peer support videos; and psychoeducational information related to pain, stress, and mindfulness.
Study: NCT02336230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: remestemcel-L
Description: Participants were treated with IV remestemcel-L at a dose of 2 x 10\^6 MSC/kg (actual body weight at screening) twice per week for each of 4 consecutive weeks. Infusions were administered at least 3 days apart and no more than 5 days apart for any infusion.
Study: NCT04252131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cassia seed tablet
Description: traditional Chinese herbs

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: cassia seed tablet
Description: traditional Chinese herbs
Study: NCT02172638

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fast-Track Protocol

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Usual management
Study: NCT02463279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sinusys Dilation System
Description: Dilation of frontal recess and/or sphenoid sinus ostia
Study: NCT02183168

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meloxicam tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin
Study: NCT03645733

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lower Temperature Group
Description: Dialysate temperature of 35 degree centigrade. The intervention group will start off using a dialysate temperature that is 36 °C. Thereafter the dialysate temperature will be reduced every two week by 0.5 °C until 35 °C or the lowest tolerated temperature reached.
Study: NCT03740659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin + Dexamethasone
Description: Levofloxacin + Dexamethasone ophthalmic solution + dexamethasone 21-phosphate administered twice: 90(±15) min. and 60(±15) min. before limbal paracentesis.
Study: NCT03976674

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: 5 group sessions (2h30/session) before the surgery
Study: NCT03289182

Intervention type: DRUG
Intervention: MabThera
Description: Participants will be administered MabThera 1400 mg (NHL) or 1600 mg (CLL) at the discretion of the physician in accordance with local clinical practice and local labeling.
Study: NCT00940446

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Insorb staples
Description: absorbable staples required for wound closure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: metal staples (Ethicon metal stapler)
Description: wound closure with metal staples
Study: NCT04734366

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Uterine closure with Baseball suture technique
Description: A simple running (continuous) baseball suture is essentially an interrupted sutures. Applied as inside to outside/inside to outside of incision.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Single Layer Continuous Locked
Description: Suturing is continued by passing through the previous stitch.
Study: NCT03740659

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: Levofloxacin ophthalmic solution (Oftaquix®) administered twice: 90 (±15) min. and 60 (±15) min. before limbal paracentesis).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone ophthalmic solution (Tamesad®) administered twice: 90 (±15) min. and 60 (±15) min. before Limbal paracentesis.
Study: NCT00931931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV1716

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HSV1716
Study: NCT03766659

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MOSE
Description: EUS-FNB with MOSE

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: ROSE
Description: EUS-FNA with ROSE
Study: NCT02434770

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BioFarma Bivalent Oral Poliomyelitis Vaccine
Description: Each dose of the WHO prequalified Bio Farma bOPV (2 drops, 0.1 ml) contains attenuated Sabin strains of poliovirus serotypes 1 and 3, with at least 10\^6 and 10\^5.8 infective units per dose, respectively.
Study: NCT03196752

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laryngeal handshake
Description: palpate for the cricothyroid membrane using the laryngeal handshake technique

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: simple palpation
Description: conventional
Study: NCT02170246

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan
Study: NCT01451424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: vaginal suppository, daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: vaginal suppository, daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: vaginal suppository, daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: vaginal suppository, daily, for 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proellex
Description: vaginal suppository, daily, for 12 weeks
Study: NCT02920983

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: somofilcon A
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nelfilcon A II 2
Description: contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: omafilcon A ll 2
Description: contact lens
Study: NCT03053895

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CSDH - Bedside twist drill technique
Description: For patients randomized to bedside drainage of CSDH, the twist-drill procedure will be conducted at the patient's bedside using local anesthetic

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CSDH - Operating Room Burr-hole technique
Description: For patients randomized to burr-hole drainage, the procedure will be performed in the operating room under local or general anesthesia based on the surgeon's and anesthesiologist's judgement of the clinical stability of the patient.
Study: NCT03851016

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Story Book
Description: Life story Book is intended to allow a person the opportunity to reminisce chronologically through their life and capture their life stories into a book.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Usual Care
Description: Three weeks of Usual Care with no visits from research team
Study: NCT04269603

Intervention type: DEVICE
Group type: OTHER
Intervention: Take blood (TA-8V (Stago®)
Description: Healthy volunteers will have 3 blood samples at M0, M3 and M6.
Study: NCT00963690

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CloSys Hemostatic Device (HD)
Description: Deploy CloSys HD to achieve hemostasis

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard compression
Description: Use standard compression to achieve hemostasis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard compression
Description: Use standard compression to achieve hemostasis
Study: NCT02831270

Intervention type: PROCEDURE
Intervention: Acute normovolemic hemodilution (ANH)

Intervention type: DRUG
Intervention: hydroxyethyl starch (HES 130/0.6)
Study: NCT01384084

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POP repair plus mini-sling
Description: For POP, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum.~A mini sling system will be used, placing a urethral low-tension tape anchored to the obturator muscles bilaterally at the level of tendinous arc. This mini-sling is a polypropylene monofilament mesh.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: POP repair
Description: For POP repair, the anterior vaginal wall is dissected from the bladder to expose a vaginal wall area where the mesh will be attached. The procedure is repeated for the posterior vaginal wall. The sacral promontory surface is prepared and 1 non-reabsorbable sutures are placed into the sacral periosteum. The peritoneum is closed over the meshes.
Study: NCT02696356

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRN-1201
Description: GRN-1201 is a vaccine comprised of 4 peptides

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: GRN-1201
Description: GRN-1201 is a vaccine comprised of 4 peptides

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GRN-1201
Description: GRN-1201 is a vaccine comprised of 4 peptides
Study: NCT04568252

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wristband with millimeter wave emission.
Description: Wristband treatment with millimeter wave emission twice a day for 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Placebo of wristband with millimeter wave emission.
Description: Treatment with a millimeter wave emission wristband placebo twice a day for 3 months.
Study: NCT03640065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: freeze-dried probiotic sachets
Description: * The participants will be instructed to consume the sachets as follow, each sachet powder is mixed with 10 ml of water in a measuring cup, then swish the mixture in the mouth for one minute before swallowing.~* This procedure will be repeated once daily for the following 4 weeks.~* 4 weeks supply will be given to the participants.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fermented dairy product ( yogurt)
Description: * The participants will be instructed to consume the yogurt once daily regularly for the following 4 weeks.~* 4 weeks supply will be given to the participants with instruction to store the yogurt in refrigerator at home
Study: NCT03553316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101-002
Description: -(Single) PK101-002

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PK101-002
Description: -(Single) PK101-002

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PK101
Description: -(Combination) PK101-001, PK101-002

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PK101
Description: -(Combination) PK101-001, PK101-002